CJH Stock Overview
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CanSino Biologics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.34 |
| 52 Week High | HK$4.00 |
| 52 Week Low | HK$1.81 |
| Beta | 0.55 |
| 1 Month Change | 8.33% |
| 3 Month Change | 27.87% |
| 1 Year Change | n/a |
| 3 Year Change | -93.24% |
| 5 Year Change | n/a |
| Change since IPO | -32.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| CJH | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.6% | -2.2% | 2.5% |
| 1Y | n/a | -25.2% | 6.0% |
Return vs Industry: Insufficient data to determine how CJH performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how CJH performed against the German Market.
Price Volatility
| CJH volatility | |
|---|---|
| CJH Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CJH has not had significant price volatility in the past 3 months.
Volatility Over Time: CJH's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,494 | Xuefeng Yu | www.cansinotech.com |
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.
CanSino Biologics Inc. Fundamentals Summary
| CJH fundamental statistics | |
|---|---|
| Market cap | €1.11b |
| Earnings (TTM) | -€194.37m |
| Revenue (TTM) | €47.63m |
12.6x
P/S Ratio-3.1x
P/E RatioIs CJH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CJH income statement (TTM) | |
|---|---|
| Revenue | CN¥370.81m |
| Cost of Revenue | CN¥781.88m |
| Gross Profit | -CN¥411.06m |
| Other Expenses | CN¥1.10b |
| Earnings | -CN¥1.51b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.13 |
| Gross Margin | -110.85% |
| Net Profit Margin | -408.10% |
| Debt/Equity Ratio | 47.5% |
How did CJH perform over the long term?
See historical performance and comparison